Neovacs To Initiates Phase-II Study Of TNF Kinoid

Neovacs plans to initiate a phase-II study of its TNF Kinoid, subject to regulatory consent, in rheumatoid arthritis patients who have failed treatment with at least one TNF inhibitor.

The proposed trial will initially test two dose levels of the TNF Kinoid, with the option of expanding recruitment and extending follow up in one dose group on the basis of serological and clinical responses.

The multicentre, Europe wide trial received significant public funding from OSEO, the French state innovation agency.

GuyCharles Fanneau de La Horie, CEO of Neovacs, said: “With all the initial dose groups having received the Kinoid, we have not seen any significant adverse reactions; importantly, it is very clear that the Kinoid does not induce cell mediated immunity.”

Furthermore, all the patients in the higher dose groups treated to date have mounted an antibody response and are in clinical remission. It makes sense to take a further step forward by testing the Kinoid in a Phase II rheumatoid arthritis trial. We are grateful for the public funding that is enabling us to expand our clinical efforts without delay,” he added.